共 9 条
- [1] Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study[J]. ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 1 - 7Atalay, Selmavan den Reek, Juul M. P. A.Otero, Marisol E.Njoo, Marcellus D.Mommers, Johannes M.Ossenkoppele, Paul M.Koetsier, Marjolein, IBerends, Maartje M.van de Kerkhof, Peter C. M.Groenewoud, Hans M. M.den Broeder, Alfons A.de Jong, Elke M. G. J.Kievit, Wietske
- [2] Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial[J]. JAMA DERMATOLOGY, 2020, 156 (06) : 649 - 658Blauvelt, AndrewLeonardi, Craig L.Gooderham, MelindaPapp, Kim A.Philipp, SandraWu, Jashin J.Igarashi, AtsuyukiFlack, MaryGeng, ZiqianWu, TianshuangCamez, AnneWilliams, DavidLangley, Richard G.
- [3] Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis[J]. JAMA DERMATOLOGY, 2024, 160 (09) : 953 - 963Eyerich, KilianAsadullah, KhusruPinter, AndreasWeisenseel, PeterReich, KristianPaul, CarleSabat, RobertWolk, KerstinEyerich, StefanieLauffer, FelixAngsana, JuliantyTaut, Friedemann J. H.Kohler, KristenChen, YanqingSendecki, JocelynLeung, Monica W. L.Wegner, SvenPersonke, YvonneGomez, MarioKrueger, NenjaTabori, SarahSchaekel, Knut
- [4] Is risankizumab as needed administration a good option for patients with plaque psoriasis?[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (09) : E713 - E715Gisondi, P.Maurelli, M.Bellinato, F.Girolomoni, G.
- [5] Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (07) : 1707 - +Mehta, HeenaMashiko, ShunyaAngsana, JuliantyRubio, ManuelHsieh, Ya-Ching M.Maari, CatherineReich, KristianBlauvelt, AndrewBissonnette, RobertMunoz-Elias, Ernesto J.Sarfati, Marika
- [6] Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning[J]. FRONTIERS IN MEDICINE, 2022, 9Queiro, RubenSeoane-Mato, DanielLaiz, AnaAgirregoikoa, Eva GalindezMontilla, CarlosPark, Hye SangTasende, Jose Pinto A.Baute, Juan Jose BethencourtIbanez, BeatrizJovenToniolo, ElideRamirez, JulioGarcia-Hinojosa, Cristina Pruenza
- [7] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) : 418 - 431Reich, KristianArmstrong, April W.Foley, PeterSong, MichaelWasfi, YasmineRandazzo, BruceLi, ShuShen, Y. -K.Gordon, Kenneth B.
- [8] Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (06) : 891 - 904Torres, TiagoPuig, LuisVender, RonYeung, JensenCarrascosa, Jose-ManuelPiaserico, StefanoGisondi, PaoloLynde, CharlesFerreira, PauloBastos, Pedro MendesDauden, EstebanLeite, LuizValerio, Joanadel Alcazar-Viladomiu, ElenaRull, Eva VilarrasaLlamas-Velasco, MarPirro, FedericoMessina, FrancescoBruni, ManfredoLicata, GaetanoRicceri, FedericaNidegger, AlessiaHugo, JanMufti, AsfandyarDaponte, Athina-IoannaTeixeira, LaetitiaBalato, AnnaRomanelli, MarcoPrignano, FrancescaGkalpakiotis, SpyridonConrad, CurdinLazaridou, ElizabethRompoti, NataliaPapoutsaki, MarinaNogueira, MiguelChiricozzi, Andrea
- [9] Anti-IL 23 biologics for the treatment of plaque psoriasis[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1489 - 1502Vu, AlanUlschmid, CadenGordon, Kenneth B.